Development of a core outcome set based on Case Report Form (CRF) to assess laboratory biomarkers and clinical parameters in Onco-Hematology area by Mariangela Vanalli & Francesca Rio
POSTER PRESENTATION Open Access
Development of a core outcome set based on
Case Report Form (CRF) to assess laboratory
biomarkers and clinical parameters in
Onco-Hematology area
Mariangela Vanalli1*, Francesca Rio2
From The 4th Meeting of the Core Outcome Measures in Effectiveness Trials (COMET) Initiative
Rome, Italy. 19-20 November 2014
Background
The number of cases, the crude and age-standardized
incidence, mortality rates and the prevalence propor-
tions estimated by the Italian Association of Cancer
Registries (AIRTUM) presently providing the epidemio-
logical indicators for the major cancers used in ICD-O-
3.1 [1-3]. By 2012, the breast cancer incidence in
women (age 25±over 85 years) was about 29%; trends
for stomach and colorectal cancer were about 5% and
14% for both genders (age 35/45±over 85 years); the
lung cancer incidence rates was about 15% in men (age
45±over 85 years) and 6% in women (age 40±over 85)
in 2009 [4,5]. From 2011 onwards the tendency chan-
ged: the female rates (20 per 100,000) increased much
more rapidly than the male rates [6].
Aim of this study is to examine the relationships
among the incidence of genera-cancer-associated risk
factors and routine laboratory in cancer patients
through CRF.
Materials and Methods
The CRF database has been developed by a dedicated
working group using Delphi process. It contain anon-
ymous records on patient characteristics (gender, age,
alcohol and smoking history, height, body weight, per-
formance status measured using the Eastern Cooperative
Oncology Group-ECOG PS, chronic comorbidities
weighted by the Charlson Comorbidity Index-CCI, type
and stage of tumor) (Figure 1) [7-9] and one set of
biomarker laboratory data identified in several variables
(Table 1) [10,11].
Results
Between 2012 and 2014, 1373 cancer patients were
enrolled at three Italian Oncological Institutions after
informed consent. Among these patients, 36% were men
and 64% were women (mean age 71±45 years) (Figure 2)
and breast was the most frequent type cancer (43%) fol-
lowed by lung (29%), colon-rectum (18%) and stomach
(9%). 72% (n=85) of the lung, 67% (n=24) of the stomach,
33% (n=25) of the colon-rectum, 4% (n=7) of the breast
cancer patients had comorbidities weighted with 3 point
and above (Age Unadjusted Charlson-Comorbidity-
Index≥4; HR=6.38; 99% CI [3.07,13.24]) [12,13] (Figure 3).
Multivariate analysis determined that comorbidity was
highly associated with cancer type, stage and ECOG PS
(p=0.01) (Figure 4). Evaluation between cardiovascular
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Fig 1 Charlson Comorbidity Index Acces.
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disease, risk of bleeding, deep-vein thrombosis and colon-
rectum cancer stage (p=0.01), breast (p=0.03), lung
(p=0.01) compared into comorbidities (Figure 5). The
other tested variables: Hgb level, neutrophil and platelet
counthad had the strongest relationship with breast, lung
cancer stage (p=0.02), stomach (p=0.002) and colon-
rectum (p=0.1) [14,15].
Conclusions
The appropriateness of results could be useful to better
describe the role of CRF and biomarkers recorded in
patient charts as well as the other variables could allow
nurses to identify patients at risk for shorter survival
time following hospitalization [16,17].
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Table 1. Multivariate Analyses of cancer type,









HCT_cod 0.105 0.708 0.387 0.078
Hb_cod 0.035 0.775 0.466 0.351
RBC_cod 0.564 0.343 0.194 0.448
WBC_cod 0.292 0.172 0.930 0.583
PLT_cod 0.167 0.535 0.401 0.332
CCI_SCORE ≥4 0.495 0.029 0.092 0.381
cancer type: breast, colon-rectum, stomach and lung; biomarkers laboratory:
HCT, Hb, RBC, WBC, PLT;
Fig 2 CCI and their respective point scores.
Fig 3 CCI and their respective point scores.
Fig 4 Multivariate Analysis and the comorbidities of CCI with IBM SPSS Italian version 21 statistical software.
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Fig 5 Multivariate Analysis and the comorbidities of CCI with IBM SPSS Italian version 21 statistical software.
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